Figure 4. Tet2 deficiency confers a competitive advantage to HSC/Ps in obese recipient mice.

(A) Schematic of the competitive BMT assay. Donor cells from Tet2^–/– or WT mice were mixed with Boy/J cells, and a competitive BMT assay was performed using lethally irradiated WT or Ob/Ob mice as recipients. Donor-derived chimerism was observed using antibodies against CD45.1⁺ or CD45.2⁺. (B) Representative flow cytometry profiles for donor chimerism in the PB of recipient mice measured every 4 weeks, and quantification of CD45.2⁺ cells in the PB of the indicated recipient mice. (C) Representative flow cytometry profile of Gr-1⁺CD11b⁺ double-positive cells in the PB of the indicated recipient mice, and frequency of myeloid cells in the PB and BM and spleens of competitive transplant recipients over 22 weeks. (D) Representative flow cytometry plots of myeloid blasts (c-KIT⁺CD11b⁺ double-positive cells) and frequency of myeloid blast cells in the BM of competitive transplant recipients over 22 weeks. (E) PB smears from the indicated recipient mice 22 weeks after BMT. Scale bars: 50 μm. (F) Representative flow cytometry profile of LSK cells in the BM from the indicated recipient mice, and frequency of LSK cells in the BM of competitive transplant recipients over 22 weeks (n = 4 mice per group). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005, and ****P < 0.0001, by 1-way ANOVA. Freq., frequency.